NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer

Cell

Volumn 166, Issue 4, 2016, Pages 963-976

  Chio, Iok In Christine ^a,b   Jafarnejad, Seyed Mehdi ^c   Ponz Sarvise, Mariano ^a,b   Park, Youngkyu ^a,b   Rivera, Keith ^a   Palm, Wilhelm ^d   Wilson, John ^a   Sangar, Vineet ^e   Hao, Yuan ^a   Öhlund, Daniel ^a,b   Wright, Kevin ^a,b   Filippini, Dea ^a,b   Lee, Eun Jung ^a,b   Da Silva, Brandon ^a,b   Schoepfer, Christina ^a,b   Wilkinson, John Erby ^f   Buscaglia, Jonathan M ^g   DeNicola, Gina M ^h   Tiriac, Herve ^a,b   Hammell, Molly ^a   Crawford, Howard C ^f   Schmidt, Edward E ⁱ   Thompson, Craig B ^d   Pappin, Darryl J ^a   Sonenberg, Nahum ^c   Tuveson, David A ^a,b   more..

^a Simons Center for Quantitative Biology   (United States)

^b Lustgarten Foundation Pancreatic Cancer Laboratory at Cold Spring Harbor   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g STONY BROOK UNIVERSITY   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BUTHIONINE SULFOXIMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE; K RAS PROTEIN; METHYLCELLULOSE; PROTEIN KINASE B; TRANSCRIPTION FACTOR NRF2; CYSTEINE; KRAS PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; PROTEIN P21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL MUTANT; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERVENTION STUDY; MOUSE; NONHUMAN; OXIDATION; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA TRANSLATION; TRANSLATION INITIATION; TRANSLATION REGULATION; ANIMAL; AUTOCRINE EFFECT; CYTOPLASM; METABOLISM; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AUTOCRINE COMMUNICATION; CYSTEINE; GLUTATHIONE; HUMANS; MICE; NF-E2-RELATED FACTOR 2; ORGANOIDS; PANCREATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 84979776414     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.06.056     Document Type: Article

References (59)

1. Anastasiou, D., Poulogiannis, G., Asara, J.M., Boxer, M.B., Jiang, J.K., Shen, M., Bellinger, G., Sasaki, A.T., Locasale, J.W., Auld, D.S., et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334 (2011), 1278–1283.
2. Ardito, C.M., Grüner, B.M., Takeuchi, K.K., Lubeseder-Martellato, C., Teichmann, N., Mazur, P.K., Delgiorno, K.E., Carpenter, E.S., Halbrook, C.J., Hall, J.C., et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22 (2012), 304–317.
3. Bar-Sagi, D., Feramisco, J.R., Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science 233 (1986), 1061–1068.
4. Barford, D., The role of cysteine residues as redox-sensitive regulatory switches. Curr. Opin. Struct. Biol. 14 (2004), 679–686.
5. Belalcázar, A.D., Ball, J.G., Frost, L.M., Valentovic, M.A., Wilkinson, J. 4th, Transsulfuration is a significant source of sulfur for glutathione production in human mammary epithelial cells. ISRN Biochem., 2013, 2014, 637897.
6. Bilanges, B., Stokoe, D., Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies. Oncogene 26 (2007), 5973–5990.
7. Boj, S.F., Hwang, C.I., Baker, L.A., Chio, I.I., Engle, D.D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M.S., et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160 (2015), 324–338.
8. Brandes, N., Reichmann, D., Tienson, H., Leichert, L.I., Jakob, U., Using quantitative redox proteomics to dissect the yeast redoxome. J. Biol. Chem. 286 (2011), 41893–41903.
9. Choo, A.Y., Blenis, J., Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 8 (2009), 567–572.
10. Davies, B.R., Logie, A., McKay, J.S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., Smith, P.D., AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther. 6 (2007), 2209–2219.
11. DeNicola, G.M., Karreth, F.A., Humpton, T.J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K.H., Yeo, C.J., Calhoun, E.S., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475 (2011), 106–109.
12. Fan, X., Chen, P., Tan, H., Zeng, H., Jiang, Y., Wang, Y., Wang, Y., Hou, X., Bi, H., Huang, M., Dynamic and coordinated regulation of KEAP1-NRF2-ARE and p53/p21 signaling pathways is associated with acetaminophen injury responsive liver regeneration. Drug Metab. Dispos. 42 (2014), 1532–1539.
13. Gingras, A.C., Gygi, S.P., Raught, B., Polakiewicz, R.D., Abraham, R.T., Hoekstra, M.F., Aebersold, R., Sonenberg, N., Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13 (1999), 1422–1437.
14. Hayes, J.D., Dinkova-Kostova, A.T., The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 39 (2014), 199–218.
15. Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban, R.H., Rustgi, A.K., Chang, S., Tuveson, D.A., Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 (2005), 469–483.
16. Huang, W., Sherman, B.T., Lempicki, R.A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4 (2009), 44–57.
17. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J., Cancer statistics, 2009. CA Cancer J. Clin. 59 (2009), 225–249.
18. Johnson, L.F., Williams, J.G., Abelson, H.T., Green, H., Penman, S., Changes in RNA in relation to growth of the fibroblast. III. Posttranscriptional regulation of mRNA formation in resting and growing cells. Cell 4 (1975), 69–75.
19. Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008), 1801–1806.
20. Ke, B., Shen, X.D., Zhang, Y., Ji, H., Gao, F., Yue, S., Kamo, N., Zhai, Y., Yamamoto, M., Busuttil, R.W., Kupiec-Weglinski, J.W., KEAP1-NRF2 complex in ischemia-induced hepatocellular damage of mouse liver transplants. J. Hepatol. 59 (2013), 1200–1207.
21. Khansari, N., Shakiba, Y., Mahmoudi, M., Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat. Inflamm. Allergy Drug Discov. 3 (2009), 73–80.
22. Ling, J., Söll, D., Severe oxidative stress induces protein mistranslation through impairment of an aminoacyl-tRNA synthetase editing site. Proc. Natl. Acad. Sci. USA 107 (2010), 4028–4033.
23. Maehama, T., Dixon, J.E., The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273 (1998), 13375–13378.
24. Malec, V., Gottschald, O.R., Li, S., Rose, F., Seeger, W., Hänze, J., HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. Free Radic. Biol. Med. 48 (2010), 1626–1635.
25. Mavrakis, K.J., Wendel, H.G., Translational control and cancer therapy. Cell Cycle 7 (2008), 2791–2794.
26. Mendoza, M.C., Er, E.E., Blenis, J., The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36 (2011), 320–328.
27. Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., Motohashi, H., Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22 (2012), 66–79.
28. Molife, L.R., Yan, L., Vitfell-Rasmussen, J., Zernhelt, A.M., Sullivan, D.M., Cassier, P.A., Chen, E., Biondo, A., Tetteh, E., Siu, L.L., et al. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J. Hematol. Oncol., 7, 2014, 1.
29. Molina-Arcas, M., Hancock, D.C., Sheridan, C., Kumar, M.S., Downward, J., Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov. 3 (2013), 548–563.
30. Moore, P.S., Sipos, B., Orlandini, S., Sorio, C., Real, F.X., Lemoine, N.R., Gress, T., Bassi, C., Kloppel, G., Kalthoff, H., et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. 439 (2001), 798–802.
31. Niture, S.K., Jaiswal, A.K., Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J. Biol. Chem. 287 (2012), 9873–9886.
32. Otto, G.A., Puglisi, J.D., The pathway of HCV IRES-mediated translation initiation. Cell 119 (2004), 369–380.
33. Palm, W., Park, Y., Wright, K., Pavlova, N.N., Tuveson, D.A., Thompson, C.B., The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1. Cell 162 (2015), 259–270.
34. Patel, M.R., Jay-Dixon, J., Sadiq, A.A., Jacobson, B.A., Kratzke, R.A., Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC. J. Thorac. Oncol. 8 (2013), 1142–1147.
35. Paulsen, C.E., Carroll, K.S., Orchestrating redox signaling networks through regulatory cysteine switches. ACS Chem. Biol. 5 (2010), 47–62.
36. Pelletier, J., Graff, J., Ruggero, D., Sonenberg, N., Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 75 (2015), 250–263.
37. Permyakov, S.E., Zernii, E.Y., Knyazeva, E.L., Denesyuk, A.I., Nazipova, A.A., Kolpakova, T.V., Zinchenko, D.V., Philippov, P.P., Permyakov, E.A., Senin, I.I., Oxidation mimicking substitution of conservative cysteine in recoverin suppresses its membrane association. Amino Acids 42 (2012), 1435–1442.
38. Raught, B., Gingras, A.C., Gygi, S.P., Imataka, H., Morino, S., Gradi, A., Aebersold, R., Sonenberg, N., Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J. 19 (2000), 434–444.
39. Ross, P.L., Huang, Y.N., Marchese, J.N., Williamson, B., Parker, K., Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3 (2004), 1154–1169.
40. Ruggero, D., Sonenberg, N., The Akt of translational control. Oncogene 24 (2005), 7426–7434.
41. Sahin, U., Weskamp, G., Kelly, K., Zhou, H.M., Higashiyama, S., Peschon, J., Hartmann, D., Saftig, P., Blobel, C.P., Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. 164 (2004), 769–779.
42. Sayin, V.I., Ibrahim, M.X., Larsson, E., Nilsson, J.A., Lindahl, P., Bergo, M.O., Antioxidants accelerate lung cancer progression in mice. Sci. Transl. Med., 6, 2014, 221ra15.
43. Semenza, G.L., HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 123 (2013), 3664–3671.
44. Sethuraman, M., McComb, M.E., Huang, H., Huang, S., Heibeck, T., Costello, C.E., Cohen, R.A., Isotope-coded affinity tag (ICAT) approach to redox proteomics: identification and quantitation of oxidant-sensitive cysteine thiols in complex protein mixtures. J. Proteome Res. 3 (2004), 1228–1233.
45. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J. Clin. 65 (2015), 5–29.
46. Socinski, M.A., Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. Clin. Cancer Res. 10 (2004), 4210s–4214s.
47. Sonenberg, N., Hinnebusch, A.G., Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136 (2009), 731–745.
48. Talalay, P., Fahey, J.W., Healy, Z.R., Wehage, S.L., Benedict, A.L., Min, C., Dinkova-Kostova, A.T., Sulforaphane mobilizes cellular defenses that protect skin against damage by UV radiation. Proc. Natl. Acad. Sci. USA 104 (2007), 17500–17505.
49. Trachootham, D., Lu, W., Ogasawara, M.A., Nilsa, R.D., Huang, P., Redox regulation of cell survival. Antioxid. Redox Signal. 10 (2008), 1343–1374.
50. Ueda, T., Watanabe-Fukunaga, R., Fukuyama, H., Nagata, S., Fukunaga, R., Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol. Cell. Biol. 24 (2004), 6539–6549.
51. Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al. NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Sci. Transl. Med., 8, 2016, 334ra51.
52. Wendel, H.G., De Stanchina, E., Fridman, J.S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., Lowe, S.W., Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004), 332–337.
53. Wilson, J.E., Powell, M.J., Hoover, S.E., Sarnow, P., Naturally occurring dicistronic cricket paralysis virus RNA is regulated by two internal ribosome entry sites. Mol. Cell. Biol. 20 (2000), 4990–4999.
54. Yang, W.S., Stockwell, B.R., Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 15 (2008), 234–245.
55. Yap, T.A., Yan, L., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K., Baird, R.D., Delgado, L., Taylor, A., Lupinacci, L., et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 29 (2011), 4688–4695.
56. Ying, H., Kimmelman, A.C., Lyssiotis, C.A., Hua, S., Chu, G.C., Fletcher-Sananikone, E., Locasale, J.W., Son, J., Zhang, H., Coloff, J.L., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149 (2012), 656–670.
57. Yun, J., Mullarky, E., Lu, C., Bosch, K.N., Kavalier, A., Rivera, K., Roper, J., Chio, I.I., Giannopoulou, E.G., Rago, C., et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350 (2015), 1391–1396.
58. Zetterberg, A., Larsson, O., Wiman, K.G., What is the restriction point?. Curr. Opin. Cell Biol. 7 (1995), 835–842.
59. Zhao, X., Gao, S., Ren, H., Sun, W., Zhang, H., Sun, J., Yang, S., Hao, J., Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Cancer Res. 74 (2014), 2455–2464.